Supplement
Tirzepatide
Dual GIP/GLP-1: the current efficacy leader.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA approved as Mounjaro (2022, type 2 diabetes) and Zepbound (2023, obesity). We grade Tirzepatide A- on evidence and C for worth-it at about $1000+ without insurance (US) per month.
Evidence
Worth it
Typical cost: $1000+ without insurance (US)/month
What it does
Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA approved as Mounjaro (2022, type 2 diabetes) and Zepbound (2023, obesity). SURMOUNT-1 showed about 20.9% mean weight loss at 72 weeks on the 15 mg dose.
What the research says
Weight loss in obesity
Evidence: strong. SURMOUNT-1: ~20.9% at 72 weeks, the largest effect in the class to date.
DRAFT: large RCTs, approved indications; everything beyond that is off-label.
Is it worth it?
DRAFT: same story as semaglutide: works, costs a lot without coverage.
Typical cost
$1000+ without insurance (US)/month
Common form, not a brand recommendation
Dosage contextestablished
Zepbound: up to 15 mg weekly titration. Only as prescribed.
Safety notes
PRESCRIPTION DRUG: GI side effects common; same rare pancreatitis/gallbladder cautions as the class. Only under a prescriber's care. Talk to your doctor. This page is information, not medical advice.
Longevity Lab Report
Tirzepatide news, graded when it happens.
New studies, dose debates, and expert shifts on tirzepatide, in one email a week. Free.
Changelog
Last updated 2026-10-15
- 2026-10-15|Batch 3 entry, DRAFT. Grades provisional; expert positions unsourced unless noted.